Literature DB >> 21523770

Increased genetic susceptibility to intestinal-type gastric cancer is associated with increased activity of the RUNX3 distal promoter.

Byungho Lim1, Hyoungseok Ju, Minjin Kim, Changwon Kang.   

Abstract

BACKGROUND: The runt-related transcription factor RUNX3 plays essential roles in various types of tumors, including gastric cancer. Epigenetic changes in the methylation of the RUNX3 proximal promoter, but not common genetic changes in RUNX3, have been associated with both changes in the gene expression and development of the cancer.
METHODS: A case-control association study was conducted by genotyping 865 unrelated Korean subjects. Subsequent functional studies were performed to reveal functional implication of genetic association.
RESULTS: Several single-nucleotide polymorphisms (SNPs) in RUNX3 were significantly associated with susceptibility to intestinal-type gastric cancer (.0028 ≤ P ≤ .022) but not diffuse-type gastric cancer (.70 ≤ P ≤ .96). The risk-associated, minor variant of an intestinal-type gastric cancer-associated SNP in the RUNX3 distal promoter (rs7528484) significantly increased promoter activity in a CREB1-dependent manner. The distal promoter-derived, 33 kDa isoform of RUNX3 increased the activity of transcription factor nuclear factor kappa B (NF-κB), which had been activated by Helicobacter pylori infection, a risk factor for intestinal-type gastric cancer, and the expression of the interleukin-1β gene (IL1B), an NF-κB target genetically and functionally associated with gastric cancer. In contrast, the proximal promoter-derived, 44 kDa isoform of RUNX3 decreased both NF-κB activity and IL1B expression.
CONCLUSIONS: In addition to epigenetic changes in the RUNX3 proximal promoter, genetic changes in the distal promoter may be associated with susceptibility to intestinal-type gastric cancer by increasing promoter activity. Functionally, 2 RUNX3 isoforms may contribute differentially to intestinal-type gastric cancer susceptibility, at least in part through regulating NF-κB activity and IL1B expression.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523770     DOI: 10.1002/cncr.26161

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Approaches to integrating germline and tumor genomic data in cancer research.

Authors:  Heather Spencer Feigelson; Katrina A B Goddard; Celine Hollombe; Sharna R Tingle; Elizabeth M Gillanders; Leah E Mechanic; Stefanie A Nelson
Journal:  Carcinogenesis       Date:  2014-08-12       Impact factor: 4.944

2.  Runx1 is a tumor suppressor gene in the mouse gastrointestinal tract.

Authors:  Remond J A Fijneman; Rebecca A Anderson; Ethan Richards; Jieming Liu; Marianne Tijssen; Gerrit A Meijer; Janae Anderson; Annette Rod; Michael G O'Sullivan; Patricia M Scott; Robert T Cormier
Journal:  Cancer Sci       Date:  2012-01-19       Impact factor: 6.716

3.  Genomic single nucleotide polymorphisms in the offspring of gastric cancer patients predispose to spasmolytic polypeptide-expressing metaplasia after H. pylori infection.

Authors:  Yu-Ching Tsai; Wei-Hsin Hsiao; Sheng-Hsiang Lin; Hsiao-Bai Yang; Hsiu-Chi Cheng; Wei-Lun Chang; Cheng-Chan Lu; Bor-Shyang Sheu
Journal:  J Biomed Sci       Date:  2015-02-21       Impact factor: 8.410

4.  Association between RUNX3 gene polymorphisms in severe preeclampsia and its clinical features.

Authors:  Yanping Zhang; Tao Wang; Jin Jia; Wen Cao; Lei Ye; Yanyun Wang; Bin Zhou; Rong Zhou
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

5.  Functional Analyses of RUNX3 and CaMKIINα in Ovarian Cancer Cell Lines Reveal Tumor-Suppressive Functions for CaMKIINα and Dichotomous Roles for RUNX3 Transcript Variants.

Authors:  Karolin Heinze; Daniel Kritsch; Alexander S Mosig; Matthias Dürst; Norman Häfner; Ingo B Runnebaum
Journal:  Int J Mol Sci       Date:  2018-01-15       Impact factor: 5.923

6.  Epigenetic silencing of miR-1271 enhances MEK1 and TEAD4 expression in gastric cancer.

Authors:  Byungho Lim; Hee-Jin Kim; Haejeong Heo; Nanhyung Huh; Su-Jin Baek; Jong-Hwan Kim; Dong-Hyuck Bae; Eun-Hye Seo; Sang-Il Lee; Kyu-Sang Song; Seon-Young Kim; Yong Sung Kim; Mirang Kim
Journal:  Cancer Med       Date:  2018-06-04       Impact factor: 4.452

Review 7.  Where Epigenetics Meets Food Intake: Their Interaction in the Development/Severity of Gout and Therapeutic Perspectives.

Authors:  Philippe T Georgel; Philippe Georgel
Journal:  Front Immunol       Date:  2021-09-17       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.